What is the Edesa Biotech Inc. stock price forecast?

Edesa Biotech Inc. is currently trading at $11.17. View real-time AI analysis on Alpha Lenz.

What is Edesa Biotech Inc. insider trading activity?

View the latest insider trading data for Edesa Biotech Inc. on Alpha Lenz.

What is Edesa Biotech Inc.'s P/E ratio?

Edesa Biotech Inc.'s P/E ratio is -8.8.

Edesa Biotech Inc.

NASDAQ · EDSA

$11.17

Ask about Edesa Biotech Inc.'s future dividend policy...

Alpha Chat Insight

“Edesa Biotech Inc. trades at a P/E of -8.8 (undervalued) with modest ROE of -99.6%.”

Ask for details →

Company Overview

Edesa Biotech Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for dermatological and gastrointestinal indications. The company's primary purpose is to address unmet medical needs by leveraging its proprietary research and extensive clinical expertise to create novel treatment options. Edesa Biotech Inc. specializes in small molecule drugs and biologics, targeting conditions where existing therapies are inadequate or non-existent. Notably, the company's pipeline includes potential treatments for atopic dermatitis and allergic contact dermatitis, aiming to improve patient outcomes in skin health. Situated in a competitive biotech industry, Edesa Biotech plays a significant role by contributing to medical advancement and potential breakthrough treatments in dermatology. Through its dedication to clinical trials and regulatory approvals, Edesa Biotech strives to enhance its market position and impact healthcare practices worldwide.

CEODr. Pardeep Nijhawan FRCPC, M.D.

Websitehttps://www.edesabiotech.com

SectorHealthcare

IndustryBiotechnology

Employees16

Company Statistics

FY 2025

Profile

$63.41MMarket Cap

$0.00Revenue

0.00Shares Out

16Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-8.82P/E

5.09P/B

N/AEV/Sales

-7.57EV/EBITDA

-8.66P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-82.86%ROA

-99.57%ROE

-82.19%ROIC

Financial Health

$10.79MCash & Cash Equivalents

$-9.71MNet Debt

8.66%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Edesa Biotech Inc. trades at a P/E of -8.8 (undervalued) with modest ROE of -99.6%.”

Ask for details →

Frequently Asked Questions

Edesa Biotech Inc. (ticker: EDSA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 16 employees. Market cap is $63M.

The current price is $11.17 with a P/E ratio of -8.82x and P/B of 5.09x.

ROE is -99.57%.